Naprosyne Enteric Coated (Naproxen)

Naproxen works by non‑selectively inhibiting the cyclooxygenase enzymes COX‑1 and COX‑2, which are essential for converting arachidonic acid into prostaglandins. By lowering prostaglandin levels, it reduces inflammation, pain signaling, and fever responses at the site of injury.

The specific dose of Naprosyne Enteric Coated is determined by the prescribing healthcare professional based on the patient’s condition, age, renal and hepatic function, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of naproxen in pregnancy and lactation has not been definitively established. It is generally advised to avoid NSAIDs, including naproxen, during the third trimester of pregnancy. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Naprosyne (naproxen) has a longer half‑life than many NSAIDs such as ibuprofen, allowing for less frequent dosing. Its efficacy in pain and inflammation is comparable, but the risk profile for gastrointestinal and cardiovascular events is similar to other non‑selective NSAIDs. Choice of NSAID should be individualized based on patient risk factors.

Store Naprosyne Enteric Coated tablets at ambient temperature, below 25 °C, in the original packaging. Keep the container tightly closed, protect from moisture, heat, and direct sunlight to maintain tablet integrity.

The enteric‑coated tablets are intended for oral administration. Swallow the tablet whole with a full glass of water, preferably after a meal or with food to reduce gastrointestinal irritation. Do not crush, chew, or split the tablet, as this may compromise the enteric coating.

Serious risks include gastrointestinal bleeding or ulceration, cardiovascular events such as heart attack or stroke, renal impairment, and severe skin reactions like Stevens‑Johnson syndrome. Patients should be monitored for signs of bleeding, chest pain, sudden kidney dysfunction, or rash, and seek medical attention promptly if they occur.

Individuals with a known hypersensitivity to naproxen or other NSAIDs, active gastrointestinal ulceration, severe heart failure, uncontrolled hypertension, or significant renal or hepatic impairment should not use Naprosyne. Pregnant women in the third trimester and patients on anticoagulant therapy should also avoid it unless specifically directed by a physician.